Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Google Secures Pentagon AI Deal for Classified Projects 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
BEIJING, Feb. 2, 2016 -- BeiGene, Ltd. ("BeiGene" or "the Company"), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced the pricing of its initial public offering of 6,600,000 American Depositary Shares ("ADSs"), each representing 13 of its ordinary shares, par value $0.0001 per share, at an initial public offering price of $24.00 per ADS, before underwriting discounts. In addition, BeiGene has granted the underwriters a 30-day option to purchase up to an additional 990,000 ADSs at the initial public offering price. All of the ADSs are being offered by BeiGene. The ADSs are expected to begin trading on The NASDAQ Global Select Market on February 3, 2016 under the ticker symbol "BGNE." The offering is expected to close on February 8, 2016, subject to customary closing conditions.
Goldman, Sachs & Co., Morgan Stanley and Cowen and Company are acting as joint book-running managers. Baird is acting as co-manager of the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 2, 2016. The offering will be made only by means of a prospectus, copies of which may be obtained for free from the offices of Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, or email: [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, United States, Attn.: Prospectus Department or by calling +1 (631) 274 2806.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.
CONTACT: Media/Investor Contact:
Xin Huang
US: +1 917-617-4653
China: +86 185-1406-3050
[email protected]
